Phase 2
N=8
AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation
Healthy
Bottom Line
View on ClinicalTrials.gov: NCT00075335 ↗Enrolled (actual)
8
Serious AEs
0.0%
Results posted
Feb 2018
Primary outcome: Primary: Change in Cytokine Gene Expression Profiles (84 Genes) in T Cells Following G-CSF Administration — 16 unique cytokine genes affected
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- AMD3100 (Mozobil plerixafor) (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Primary completion
- Aug 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Cytokine Gene Expression Profiles (84 Genes) in T Cells Following G-CSF Administration |
16 | — |
| PRIMARY Change in Cytokine Gene Expression Profiles (84 Genes) in T Cells Following Plerixafor Administration |
— | — |
Summary
Peripheral blood progenitor cells (PBPC) have become the preferred source of hematopoetic stem cells for allogeneic transplantation because of technical ease of collection and shorter time required for engraftment. Traditionally, granulocyte-colony stimulating factor (G-CSF) has been used to procure the peripheral blood stem cell graft. Although regimens using G-CSF usually succeed in collecting adequate numbers of PBPC from healthy donors, 5%-10% will mobilize stem cells poorly and may require multiple large volume apheresis or bone marrow harvesting. Although G-CSF is generally well tolerated in healthy donors, it may be associated with bone pain, headache, myalgia and rarely life threatening side effects like stroke, myocardial infarction and splenic rupture.
AMD3100, is a bicyclam compound that inhibits the binding of stromal cell derived factor-1 (SDF-1) to its cognate receptor CXC- chemokine receptor 4 (CXCR4). CXCR4 is present on cluster of differentiation 34 (CD34)+ hematopoetic progenitor cells and its interaction with stromal cell derived factor 1 (SDF-1) plays a pivotal role in the homing of CD34+ cells in the bone marrow. Inhibition of the CXCR4-SDF1 axis by AMD3100 releases CD34+ cells into the circulation, which can then be collected easily by apheresis.
Recently, a published report demonstrated that large numbers of CD34+ cells were rapidly mobilized in healthy volunteers following a single subcutaneous injection of AMD3100. Remarkably, the number of CD34+ cells collected by apheresis following a single injection of AMD3100 was comparable to the number of CD34+ cells collected from historical controls receiving 5 days of G-CSF prior to stem cell mobilization.
In this study we will collect PBPCs following a single subcutaneous injection of AMD3100 from healthy donors who have previously had PBPC collected using standard G-CSF mobilization. The AMD3100 mobilized cells, G-CSF mobilized cells, and circulating cells prior to both AMD3100 and G-CSF mobilization will be analyzed in terms of cellular content and function of lymphocytes, natural killer (NK) cells, and antigen presenting cells. AMD3100 mobilized PBPC will be collected for the purpose of research studies and will not be used for therapeutic purposes.
Eligibility Criteria
- INCLUSION CRITERIA:
- Mobilization and collection of PBPC using G-CSF at least 60 days prior to protocol enrollment (stem cell donors enrolled on Branch transplant protocols or healthy volunteers enrolled on 96-H-0049: Use of granulocyte colony stimulating factor mobilized leukapheresis collections from healthy volunteers).
- Ages greater than or equal to 18 years and less than or equal to 80 years.
- Normal renal function: creatinine less than 1.5 mg/dl.
- Normal liver function: total bilirubin less than 1.5mg/dl, alanine aminotransferase (ALT) 6 -41 U/L, aspartate aminotransferase (AST) 9-34 U/L.
- Normal blood count: white blood cell (WBC) 3000-10000/mm(3)
granulocytes greater than 1500/mm(3)
platelets greater than 150,000/mm(3)
hemoglobin (females greater than 11.1 g/dl, males greater than 12.7 g/dl).
- Subject must be eligible for normal blood donation and fit to undergo apheresis procedure (antecubital veins must be adequate for peripheral access during apheresis).
- Ability to comprehend the investigational nature of the study and provide informed consent.
EXCLUSION CRITERIA: Any of the Following
- Active infection or history of recurrent infection- hepatitis B and C (HBsAg, Anti-HBc, Anti-HCV), HIV and human T- lymphocytic virus (HTLV-1).
- History of autoimmune disease such as rheumatoid arthritis, systemic lupus erythematous.
- History of cancer within the past 5 years excluding basal cell or squamous cell carcinoma of the skin.
- History of any hematologic disorders including thromboembolic disease.
- History of cardiac disease such as uncontrolled hypertension, peripheral vascular disease, myocardial infarction, cardiac arrhythmias OR related symptoms such as tachycardia, chest pain, shortness of breath which have required medical intervention OR treatment or a Framingham coronary disease risk prediction score of greater than 10% 10 year coronary heart disease (CHD) risk.
- History of cerebrovascular disease, transient ischemic attack, or stroke.
- Pregnant or lactating.
- Severe psychiatric illness: mental deficiency sufficiently severe as to make informed consent impossible
Data sourced from ClinicalTrials.gov (NCT00075335). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.